



## Commercial & HealthCare Exchange PA Criteria *Effective: June 3, 2020*

**Prior Authorization:** Xcopri

**Products Affected:** Xcopri (cenobamate) oral tablets

**Medication Description:** Xcopri is approved for the treatment of partial onset seizures in adult patients. The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate reduces repetitive neuronal firing by inhibiting voltage-gated sodium currents and is a positive allosteric modulator of the gamma-aminobutyric acid (GABA-A) ion channel.

**Covered Uses:** Partial-onset seizure

**Exclusion Criteria:** Familial Short QT syndrome

**Required Medical Information:**

- 1) Diagnosis
- 2) Previous therapies tried and failed

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** Xcopri is being prescribed by, or in consultation with, a neurologist

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient must have a diagnosis of partial-onset seizures; **AND**
- B. The patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, levetiracetam, carbamazepine, lamotrigine, topiramate, phenytoin, or oxcarbazepine)

**References:**

1. Xcopri [product insert]. SK Biopharmaceuticals. Paramus, NJ. November 2019.
2. Xcopri. Lexicomp Online [Internet database], Hudson, Ohio: Wolters Kluwer Health, Inc; May 20, 2020.

Last Res. 6/3/2020



Confidential Information

This document is confidential and proprietary to ConnectiCare, Inc. Unauthorized use and distribution are prohibited.

Page 1 of 2

## Policy Revision history

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	06/03/2020

